Concurrent Investment Advisors LLC Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Concurrent Investment Advisors LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 8.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,731 shares of the life sciences company’s stock after acquiring an additional 131 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Illumina were worth $231,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ILMN. WCM Investment Management LLC lifted its stake in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after buying an additional 48,018 shares during the period. Primecap Management Co. CA lifted its stake in shares of Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after acquiring an additional 87,599 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Illumina by 4.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after acquiring an additional 54,319 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ILMN. JPMorgan Chase & Co. lifted their target price on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Morgan Stanley decreased their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Robert W. Baird upped their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and decreased their price target for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group dropped their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and an average target price of $159.45.

Illumina Trading Up 1.9 %

NASDAQ ILMN opened at $95.73 on Wednesday. Illumina, Inc. has a 1 year low of $91.92 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company has a market capitalization of $15.16 billion, a PE ratio of -12.46, a P/E/G ratio of 1.60 and a beta of 1.10. The company has a fifty day moving average of $126.02 and a 200 day moving average of $133.80.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.